Selegiline and Other Atypical Monoamine Oxidase Inhibitors in Depression
- 1 June 2001
- journal article
- Published by SLACK, Inc. in Psychiatric Annals
- Vol. 31 (6) , 385-391
- https://doi.org/10.3928/0048-5713-20010601-08
Abstract
No abstract availableThis publication has 26 references indexed in Scilit:
- Meta-Analysis of the Reversible Inhibitors of Monoamine Oxidase Type A Moclobemide and Brofaromine for the Treatment of DepressionPublished by Springer Nature ,1999
- Pressor Response to Tyramine after Single 24‐Hour Application of a Selegiline Transdermal System in Healthy MalesThe Journal of Clinical Pharmacology, 1997
- MoclobemideDrugs, 1996
- BrofaromineCNS Drugs, 1995
- Effect of Deprenyl on the Progression of Disability in Early Parkinson's DiseaseNew England Journal of Medicine, 1989
- L-deprenyl plus l-phenylalanine in the treatment of depressionJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1984
- L-Deprenil, A Selective Monoamine Oxidase Type B Inhibitor, in the Treatment of Depression: A Double Blind EvaluationThe British Journal of Psychiatry, 1983
- Antidepressant potentiation of 5-hydroxytryptophan by L-deprenil in affective illnessJournal of Affective Disorders, 1980
- L-deprenyl, a selective monoamine oxidase type-b inhibitor in endogenous depressionLife Sciences, 1980
- Anti-depressant potentiation of 5-hydroxytryptophan by L-deprenyl, an MAO ?type B? inhibitorJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1978